Expanding Patient Access to Best-in-Class Precision Therapies

Japan’s biomarker and companion diagnostics environment was undergoing significant transformation as regulatory frameworks mature and co-development approaches gained broader institutional backing. While this momentum was opening new pathways for innovation, it also exposed hurdles such as complex reimbursement mechanisms, gaps in CDx implementation infrastructure, and misalignment between global and Japan-specific development timelines.

The World Clinical Biomarkers & CDx Summit Japan stood alone as the only event built specifically to address these challenges. Covering every stage of biomarker-led drug development, from early clinical strategy through CDx launch and adoption, the summit united 80+ senior decision-makers from biopharma, diagnostics, government bodies, and healthcare systems to catalyze collaboration and advance precision medicine.

For international companies establishing a presence in Japan and local organizations seeking to expand their impact, this summit delivered the strategic insight, network, and partnerships essential to navigating Japan’s complex precision medicine landscape.